CrowdfundedWealth

Crescent Private Credit Income Q3 2026: NAV $26.38, Tender Locks

ResearchBy Jorge20 min read9 SEC filings cited

Some links pay us a referral fee; each one says so. Disclosure

Vehicle file: Crescent Private Credit Income Corp — assets, distributions, repurchases and every filing, as filed with the SEC.Open the file →

Filing alert · free

An email when Crescent Private Credit Income Corp files with the SEC

An email the day Crescent Private Credit Income Corp files something new, with the link to the document on the SEC site.

Quick answer

Crescent Private Credit Income Corp (CIK 1954360), a non-traded BDC advised by Crescent Cap NT Advisors, reported in its Form 10-Q filed November 13, 2026 (accession 0001193125-26-460859) a NAV per share of $26.38 for Class I and Class S at September 30, 2026, up from $26.26 at June 30, 2026 and down from $27.06 at December 31, 2025 (as of November 16, 2026). Net assets were $591,943 thousand on 22,441,323 shares. Third-quarter net investment income of $11,769 thousand was 99.2% of the $11,863 thousand of distributions, up from 94.9% in the second quarter (our arithmetic), but the adviser waived $1,549 thousand of income incentive fees in the quarter, and the 10-Q says that waiver ran “through September 30, 2026.” One portfolio company was on non-accrual at 0.8% of debt at cost and 0.5% at fair value. In the offer that expired September 24, 2026, holders tendered 114,939 shares and the fund bought all of them at $26.47. The Schedule TO adds a fact the 10-Q does not: some Class I owners agreed with the adviser not to tender until the third or fourth quarter of 2029, or until NAV first passes $1.5 billion.

Key takeaways

  • NAV per share has steadied after a slide. Class I went from $27.06 (December 31, 2025) to $26.26 (June 30, 2026) and $26.38 (September 30, 2026): up $0.12, or 0.5%, in the quarter and down $0.68, or 2.5%, in nine months (our arithmetic). The monthly 8-Ks show $26.33 in July, $26.47 in August and $26.38 in September. Net assets grew 7.2% in the quarter, to $591.9 million.
  • Income covered 99.2% of distributions in the third quarter, against 94.4% in the first and 94.9% in the second (our arithmetic). The step up leans on a waiver: the fund incurred $1,549 thousand of income incentive fees in the quarter and the adviser waived all of it. Had that fee been charged, income would have covered 86.2% of distributions (our arithmetic, ignoring tax effects). The 10-Q states the waiver “through September 30, 2026” and says nothing about the fourth quarter.
  • The fund is also paying the adviser back. It accrued $620 thousand of expense support reimbursement in the quarter and $1,238 thousand in nine months, and the 10-Q table of earlier expense support still shows $9,215 thousand unreimbursed (our arithmetic: sum of the table), with eligibility running to dates between August 31, 2027 and November 30, 2028.
  • Why the queue is quiet: 114,939 shares were tendered, 0.55% of shares at July 31, 2026, and 100% were accepted at $26.47 for $3,003,040.66. The Schedule TO of August 26, 2026 says certain beneficial owners of Class I shares agreed not to tender “until (i) for certain beneficial owners, the third or fourth quarter of 2029, as applicable or (ii) for certain beneficial owners, the Company’s net asset value initially surpasses $1.5 billion.” NAV of $591.9 million is 39.5% of that figure (our arithmetic).
  • New money has slowed sharply. Registered Class I sales added about $33.7 million after the August 1, 2026 closing, $6.6 million after September 1 and $2.0 million after October 1 (our arithmetic from the cumulative tables of the monthly 8-Ks), and the 10-Q reports about $450 thousand received for November 1. The $3,003 thousand paid out in September is larger than the October and November subscriptions combined, $2.4 million (our arithmetic).
  • Credit is stable but not clean. One company, Avalign Technologies, stayed on non-accrual: 0.8% of debt at cost and 0.5% at fair value, $7.8 million at cost and $4.5 million at fair value, about 57% of cost (our arithmetic). Debt was flat at $418.2 million, debt to equity 0.71x and asset coverage 240% against the 150% minimum. The fund’s chief financial officer resigned effective October 7, 2026, with no disagreement reported.

CSV · 149 rows

Crescent Private Credit Income Corp Q3 2026 10-Q: NAV, income against distributions, fee waivers, non-accrual, leverage, subscriptions and the September tender

149 rows from the Forms 10-Q for September 30 and June 30, 2026, the Forms 8-K of July 28, August 25, September 25, October 13 and October 28, 2026, the Schedule TO-I of August 26, 2026 and its final TO-I/A: NAV, net assets, income against distributions, waivers and expense support, non-accrual, portfolio mix, debt, subscriptions, the tender and its lock-up text. Form and accession number on every row.

What changed between June 30 and September 30, 2026

Our earlier page, Crescent Private Credit Income Corp: tender offers and NAV, covers the eight tender offers since 2024, who owns the shares, the fee terms and the Form 40-APP co-investment application. This page is the reading of the 10-Q for the quarter ended September 30, 2026 and the filings around it. The October 28 8-K gave the September 30 NAV; the 10-Q adds the full statements.

MeasureDecember 31, 2025June 30, 2026September 30, 2026Change in the quarter (our arithmetic)
NAV per share, Class I$27.06$26.26$26.38+$0.12 (+0.5%)
Total net assets$465.1M$552.2M$591.9M+$39.7M (+7.2%)
Shares outstanding, all classes17,187,40621,027,32322,441,323+1,414,000 (+6.7%)
Investments at fair value$879.59M$944.69M$967.55M+$22.87M (+2.4%)
Portfolio companies246185190+5
Weighted average yield at cost8.3%8.6%8.8%+0.2 points
Debt drawn on the JPM facility$420.0M$418.8M$418.2M-$0.6M
Asset coverage ratio221%230%240%+10 points
Companies on non-accrualnone1 (0.5% of debt at fair value)1 (0.5% of debt at fair value)no change

The quarter was one of growth without leverage: net assets rose $39.7 million while borrowings did not move, so debt to equity fell from 0.76x at June 30 to 0.71x at September 30 (8-K figures). The portfolio mix shifted too. Unitranche first lien loans were 60.5% of fair value against 43.6% at December 31, 2025, while senior secured first lien loans fell from 52.1% to 31.5%. The largest industry, health care equipment and services, went from 21.9% to 28.9% of fair value.

The September tender, and who agreed not to join it

The offer was filed on August 26, 2026 for up to 1,051,383 shares, 5.0% of the 21,027,649 shares outstanding at July 31, 2026 (our arithmetic: 21,020,533 Class I plus 7,116 Class S). It priced at the NAV of August 31, 2026, expired on September 24, 2026 and was paid on or about September 29, 2026.

ItemFigureSource
Shares offered for1,051,383Schedule TO-I, August 26, 2026
Shares validly tendered114,939.136Schedule TO-I/A, September 30, 2026
Share of tendered shares accepted100%Schedule TO-I/A
Tendered as a share of the offer10.9% (our arithmetic)114,939 divided by 1,051,383
Tendered as a share of shares outstanding0.55%Form 10-Q, share repurchase program table
Aggregate NAV of tendered shares$3,042,438.93Schedule TO-I/A
Cash paid on or about September 29, 2026$3,003,040.66Schedule TO-I/A
Price per share$26.47Schedule TO-I/A

The new fact is in Item 5 of the Schedule TO-I. After stating that the prospectus gives the board discretion over repurchases, it says: “Certain beneficial owners of the Company’s Class I Shares have entered into agreements with the Adviser pursuant to which such investors agreed, subject to certain agreed-upon terms and limitations, to not tender their Shares in any anticipated quarterly tender offer by the Company until (i) for certain beneficial owners, the third or fourth quarter of 2029, as applicable or (ii) for certain beneficial owners, the Company’s net asset value initially surpasses $1.5 billion.” The same filing says that “none of the officers, Directors, or affiliates of the Company intend to tender Shares in the Offer.”

Three things follow from the text. First, the filing does not say how many shares are covered or who the owners are, so the share of the fund that cannot be tendered is not known from EDGAR. Second, the two exits are different: one is a date in 2029, the other a size. Net assets of $591.9 million are 39.5% of $1.5 billion, and the nine-month gain in net assets was $126.9 million (our arithmetic), so at that pace the size condition would be later than the 2029 date, though the pace has depended on sales that have slowed (next section). Third, it fits the record on our earlier page: no shares were tendered in seven straight offers, and the first request was 0.55% of shares. A quiet queue here says little about how the fund would handle a request near the 5.0% limit.

Money in against money out

The 10-Q shows Class I issuance of $40,270 thousand in the third quarter, $48,924 thousand in the second and $142,411 thousand in nine months, against $3,003 thousand repurchased in the third quarter. The monthly 8-Ks give a finer view. Each lists registered Class I shares issued and proceeds since the offering began; the differences between filings are the sales at each month’s first closing.

Monthly 8-KRegistered Class I shares issued, cumulativeProceeds, cumulativeSales since the previous 8-K (our arithmetic)
July 28, 202614,474,664$389.4Mn/a
August 25, 202615,754,553$423.1M1,279,889 shares, about $33.7M (August 1 closing)
September 25, 202616,003,666$429.7M249,113 shares, about $6.6M (September 1 closing)
October 28, 202616,077,585$431.7M73,919 shares, about $2.0M (October 1 closing)

The August and September figures add to $40.3 million, close to the $40.27 million of Class I issuance in the 10-Q (our arithmetic), so the July 1 closing was small. The Note 12 subsequent events then show 73,920 shares sold on October 1, 2026 at $26.38 for $1,950 thousand, and about $450 thousand of subscriptions received for November 1, 2026. The fund priced those at NAV, with the October NAV expected within 20 business days of November 1.

Money in dropped from $33.7 million to $2.4 million (October plus November closings) in three months, while the September tender paid out $3.0 million. At September 30 the fund held $27,022 thousand of cash and had $231,840 thousand of undrawn capacity under its credit facility. The filings do not say why sales slowed.

Month-endNAV per shareAggregate NAVFair value of investmentsPrincipal debtDebt to equity
June 30, 2026$26.26$552.2M$944.7M$418.8M0.76x
July 31, 2026$26.33$553.7M$968.0M$426.1M0.77x
August 31, 2026$26.47$590.5M$970.9M$400.8M0.68x
September 30, 2026$26.38$591.9M$967.5M$418.2M0.71x

All figures are from the monthly Forms 8-K, which state debt to equity themselves. The September NAV is $0.09 below August (our arithmetic) in a quarter in which realized and unrealized results for the three months were a net gain of $2,531 thousand ($2,012 thousand of unrealized appreciation on non-controlled investments and $481 thousand of realized loss, with currency items making up the rest). Over nine months the same line is a net loss of $11,440 thousand. Class S shares carry the same NAV, $26.38, and only 7,153 of them were outstanding at September 30, 2026.

Is the distribution earned? Income against payout

Class I distributions were $0.165 for each of the July, August and September 2026 record dates, plus a special $0.045 for September, or $0.54 for the quarter (our arithmetic) and $1.68 over nine months. The October 2026 record date brought another $0.165. Class I earned $1.61 a share of net investment income in nine months against the $1.68 declared, 95.8% (our arithmetic).

Quarter, 2026Net investment incomeDistributions, all classesIncome as % of distributions (our arithmetic)Income if the incentive fee had been charged (our arithmetic)
First$10,741K$11,377K94.4%82.6%
Second$10,666K$11,236K94.9%82.4%
Third$11,769K$11,863K99.2%86.2%
Nine months$33,176K$34,476K96.2%83.8%

First-quarter figures are the six-month 10-Q totals less the second quarter. The right-hand column subtracts the income incentive fees the fund incurred and the adviser waived ($1,410 thousand in the second quarter, $1,343 thousand in the first by subtraction from the $2,753 thousand six-month figure, $1,549 thousand in the third) and ignores any tax effect. It is a sensitivity, not a forecast: the fee only applies above a hurdle, and the contract terms are on our earlier page.

What matters for a reader is the sentence in Note 3 of the 10-Q: “The Adviser voluntarily agreed to waive incentive fees from the Company’s inception through September 30, 2026.” The June 10-Q used the same words with June 30, 2026, and the waiver then continued through the third quarter, so the date has so far moved with each report. The 10-Q gives no commitment for the fourth quarter. The base management fee, 1.25% of net assets, is charged: $1,820 thousand incurred in the third quarter, of which $25 thousand was waived.

The expense support arrangement runs the other way. Under the Expense Support and Conditional Reimbursement Agreement of May 3, 2023 the adviser paid expenses in 2024 and 2025, and the fund repays it from income that exceeds distributions, subject to conditions on the expense ratio and the distribution rate. The fund accrued $618 thousand of reimbursement in the second quarter and $620 thousand in the third. Those payments reduce net investment income but are not part of any fee waiver. The table of past expense support shows $1,238 thousand reimbursed in total (all in 2026) and $9,215 thousand still unreimbursed.

Credit: one loan on non-accrual, marked down 43%

At September 30, 2026 one portfolio company was on non-accrual, 0.8% of total debt investments at cost and 0.5% at fair value; at June 30, 2026 the figures were 0.9% and 0.5%, and at December 31, 2025 there were none. The MD&A table shows $7.8 million of non-accrual debt at cost and $4.5 million at fair value. The schedule of investments marks the company as Avalign Technologies, Inc., which it groups under health care equipment and services: a revolver with $599 thousand of cost and $222 thousand of fair value, and a term loan with $7,173 thousand of cost and $4,241 thousand of fair value, both unitranche first lien loans maturing in December 2028.

Avalign Technologies loans (our arithmetic)CostFair valueFair value as % of cost
June 30, 2026$7,821K$4,588K58.7%
September 30, 2026$7,772K$4,463K57.4%

Cost fell $49 thousand and fair value fell $125 thousand in the quarter (our arithmetic). Nothing else was placed on non-accrual. The nine-month net realized loss on non-controlled investments was $8,059 thousand, nearly all booked before the third quarter (third-quarter realized loss, $481 thousand), and the nine-month net change in unrealized value was negative $6,396 thousand. Weighted average yield on income-producing securities was 8.8% at cost, with 98.1% of debt floating.

Leverage and the credit facility

Borrowing is one line, the JPM Funding Facility III: $650,000 thousand committed, $418,160 thousand drawn and $231,840 thousand available at September 30, 2026, against $575,000 thousand committed and $419,972 thousand drawn at December 31, 2025. The weighted average interest rate on borrowings was 5.78% for the nine months. The asset coverage ratio was 240% (230% at June 30, 2026 and 221% at December 31, 2025), against a 150% minimum for a BDC that has the stockholder approval the 10-Q describes.

Other filings since June 30, 2026

  • Chief financial officer. A Form 8-K dated October 13, 2026 (accession 0001193125-26-420418) reports that the board accepted the resignation of the fund’s chief financial officer effective October 7, 2026, “not the result of any disagreement with management or the Board,” and appointed an interim chief financial officer who also serves in that role at Crescent Capital BDC, Inc. and Crescent Capital Group LP. The October 28 8-K was signed by the interim officer.
  • Distribution and NAV 8-Ks. July 28, August 25, September 25 and October 28, 2026, the source of the monthly table above. No Form 424B3 NAV supplement appears on the fund’s EDGAR filing list from June 1 to November 16, 2026: the monthly NAV is in the 8-K.
  • Form 40-APP/A. Amendment No. 3 of October 13, 2026 is covered on our earlier page. Nothing in the 10-Q changes its status.
  • Next tender offer. No Schedule TO-I had been filed on the fund’s CIK as of November 16, 2026.

What to watch, with dates

  • Late November 2026: the October NAV 8-K (the 10-Q says it is generally available within 20 business days after November 1, 2026) and the payment of the October distribution of $0.165 for Class I, on or about November 30, 2026.
  • The fourth-quarter tender offer: the August offer was filed on August 26, 2026. A new Schedule TO-I would set the size (5.0% of shares outstanding at the end of the previous month: at 22,441,323 shares that is 1,122,066, or about $29.6 million at $26.38, our arithmetic and only a guide to scale) and the price date.
  • The incentive fee waiver after September 30, 2026: the Form 10-K for 2026, due in early 2027, will say whether it continued.
  • Monthly sales: each 8-K’s cumulative table shows whether the $2.0 million of October is a floor or a trend.

What a reader can do with this

  • If you hold Class I and want to sell: every request so far has been paid in full at NAV, and the one request was 10.9% of the offer. The risk to read is different from queue length: the board can amend, suspend or terminate the program, unfulfilled requests do not carry over, and part of the share base has agreed not to tender until 2029 or a larger NAV, which both lowers the demand in the queue and says little about a stress case.
  • If you are comparing it with other non-traded BDCs: the measures that line up are NAV change since December 31 (-2.5%), income over distributions (96.2% for nine months, 83.8% without the waiver), principal debt over net assets (0.71x per the 8-K) and non-accruals (one company, 0.5% at fair value). Our non-traded BDC list ranks the group, the tender results page shows who prorated, and the BDC non-accrual census compares credit. Our BDC explainer defines the terms.
  • Ask three questions: whether the incentive fee waiver continues into the fourth quarter and for how long; how many shares and what share of NAV are covered by the agreements not to tender; and what the October and November subscriptions say about the pace of new money.
  • Taxes: the fund intends to qualify as a regulated investment company, so distributions are reported after year-end. See our guide to estimated tax payments on REIT, BDC and K-1 income.

If a meaningful part of your savings sits in one non-traded fund, a conversation with a qualified adviser about how it fits the rest of your holdings and your next tender decision may be worth having.

FAQ

All figures are from SEC EDGAR filings of Crescent Private Credit Income Corp (CIK 1954360) read on November 16, 2026: the Form 10-Q for September 30, 2026 (accession 0001193125-26-460859, filed November 13, 2026), the Form 10-Q for June 30, 2026 (0001193125-26-352548), the Forms 8-K of July 28, 2026 (0001193125-26-320979), August 25, 2026 (0001193125-26-365148), September 25, 2026 (0001193125-26-402850), October 13, 2026 (0001193125-26-420418) and October 28, 2026 (0001193125-26-436171), the Schedule TO-I of August 26, 2026 (0001193125-26-368756) and its final Schedule TO-I/A of September 30, 2026 (0001193125-26-407911). The last filing on the fund’s CIK was the Form 10-Q of November 13, 2026. Ratios, sums, percentages and worked examples are our arithmetic. This is analysis of public documents, not investment, legal or tax advice.

Affiliate Disclosure: Some links are affiliate links. We may earn a commission at no extra cost to you. This does not affect our ratings. Learn more.